scout
Opinion|Videos|January 31, 2025

CheckMate-67T Trial Design

Panelists discuss the FDA approval of subcutaneous nivolumab based on the CheckMate-67T trial findings, highlighting its potential to improve patient convenience and treatment adherence while maintaining efficacy in the treatment of melanoma.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME